@article{article_476330, title={The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis}, journal={Marmara Medical Journal}, volume={32}, pages={44–49}, year={2019}, DOI={10.5472/marumj.476330}, author={Vatansever, Sezgin and Paköz, Zehra Betül}, keywords={Non-alcoholic steatohepatitis,Cirrhosis,Mortality}, abstract={<p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">Objectives: Cirrhosis is seen in 4-8% of patients with nonalcoholic </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">fatty liver disease (NAFLD), and death occurs in 1-5% </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">of them due to hepatocellular carcinoma (HCC). The aim of this </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">study was to determine the factors associated with complications </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">and mortality in patients with cirrhosis secondary to non-alcoholic </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">steatohepatitis (NASH). </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">Materials and Methods: The patients with cirrhosis due to </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">NASH diagnosed between 2008 and 2018 in our clinic formed </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">the study population. Patients with diabetes, obesity, or insulin </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">resistance and those with cirrhosis due to other causes were </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">excluded. The patients were enrolled and followed up prospectively. </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">Results: A total of 185 patients were included in the study. </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">The survival was 94.6% at the 1st year and 57.0% at the 5th year. </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">Median survival duration was 5.83 years. The rate of HCC </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">development was 0.7% at the 1st year and 9.7% at the 5th year. In </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">the multivariate Cox analysis, age (OR: 1.12, 95% CI: 1.04-1.21; </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">P = 0.003), creatinine (OR: 24.4, 95% CI: 2.32-257.8; P= 0.008) </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">and encephalopathy (OR: 24.49, 95% CI: 1.06-19.6; p = 0.042) </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">were found as independent predictors of mortality. Development </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">of ascites occurred in 46.9%, variceal bleeding in 21.9% and </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">encephalopathy in 18% of patients at the 5th year. </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">Conclusion: Patients with NASH-related cirrhosis should </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">be carefully monitored for HCC development, variceal bleeding, </span> </font> </p> <p class="MsoNormal" style="line-height:150%;"> <font face="Times New Roman, serif"> <span style="font-size:16px;">ascites, and encephalopathy. </span> </font> </p>}, number={1}, publisher={Marmara University}